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Proteasomes are multicatalytic protease complexes in the cell, involved in the non-lysosomal recycling of
intra-cellular proteins. Proteasomes play a critical role in regulation of cell division in both normal as well as cancer
cells. In cancer cells this homeostatic function is deregulated leading to the hyperactivation of the proteasomes.
Proteasome inhibitors (PIs) are a class of compounds, which either reversibly or irreversibly block the activity of
proteasomes and induce cancer cell death. Interference of PIs with the ubiquitin proteasome pathway (UPP)
involved in protein turnover in the cell leads to the accumulation of proteins engaged in cell cycle progression,
which ultimately put a halt to cancer cell division and induce apoptosis. Upregulation of many tumor suppressor
proteins involved in cell cycle arrest are known to play a role in PI induced cell cycle arrest in a variety of cancer
cells. Although many PIs target the proteasomes, not all of them are effective in cancer therapy. Some cancers
develop resistance against proteasome inhibition by possibly activating compensatory signaling pathways.
However, the details of the activation of these pathways and their contribution to resistance to PI therapy remain
obscure. Delineation of these pathways may help in checking resistance against PIs and deducing effective
combinational approaches for improved treatment strategies. This review will discuss some of the signaling
pathways related to proteasome inhibition and cell division that may help explain the basis of resistance of some
cancers to proteasome inhibitors and underline the need for usage of PIs in combination with traditional
chemotherapy.
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Cancer cells differ from the normal cells of the body in
their ability to divide indefinitely and evade programmed
cell death [1]. In normal cells, the cell cycle is controlled
by a complex series of signaling pathways by which a cell
grows, replicates its DNA and divides. This process also
includes mechanisms which ensure that any errors therein
are corrected, and if not, the cells commit suicide in a sys-
tematic cellular process known as programmed cell death
or apoptosis. In cancer, as a result of genetic mutations,
this regulatory process malfunctions, resulting in uncon-
trolled cell proliferation. Alteration in these mechanisms
commonly affect the expression of cell cycle regulatory
proteins, causing overexpression of cyclins and loss of ex-
pression of cyclin dependent kinase inhibitors (CKIs).
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Cell Death Research Laboratory, Division of Endocrinology, CSIR- Central
Drug Research Institute, Lucknow 226001, India
© 2012 Rastogi and Mishra; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumhave long been viewed as potential targets for anticancer
therapeutics. Despite years of research and attempts direc-
ted at inhibiting cell cycle kinases or cell cycle regulating
transcription factors, most of these approaches have not
been successfully translated to the clinic as cancer thera-
peutics [2]. Therefore, targeting the pathways which bring
about timely degradation of these proteins i.e. Proteasome
pathway, provided the rationale for targeted anticancer
drug development.
Cells normally depend upon two important pathways
for degradation of cellular proteins, i.e. 1. the aggre-
some/lysosome pathway for extracellular proteins and 2.
the ubiquitin proteasome pathway ( UPP) for intracellu-
lar proteins [3]. Proteasomes, key complexes of the latter
pathway, are multicatalytic protease complexes engaged
in non-lysosomal recycling of intra-cellular proteins of
short life span. These small protein degradation machi-
nes are present ubiquitously in both cytoplasm and nu-
cleus of mammalian cells. These are constituted of aentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 List of proteasome inhibitors natural and
synthetic in pre-clinical studies and clinical trials
FDA approved*/ In Clinical trials In preclinical Studies
Synthetic Natural Synthetic Natural
Bortezomib*[9] NPI-0052 [13] CEP-18770 [12] Celastrol [14]
Carfilzomib (PR-171) [16] Shikonin [16]
MLN9708 [16] EGCG [18]
Curcumin [19]
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catalytic core capped by a 19S regulatory subunit at both
ends [3]. They guide the proteolytic cleavage and recycling
of proteins whose functions are needed to be checked on
a timely and stage specific manner [4-7]. Target proteins
of the UPP consist of a polyubiquitin chain covalently
attached to their lysine residues. This ubiquitin tag is
recognized by the 19S regulatory subunit of the prote-
asome and the tagged protein is degraded in a ATP de-
pendent manner [8]. Apart, from their presence in healthy
cells they are found to be highly expressed and active in
cancer cells. In cancer cells, proteasomes are engaged in
proteolysis of many tumor suppressor proteins related to
cell division. Owing to their established role in cancer pro-
gression, several compounds with proteasome inhibition
activity has been tested and recognized as potential anti-
cancer drugs against hematological malignancies and
some solid cancers [9-12]. Based on their mode of action,
compounds having proteasome inhibitory activity have
either reversible or irreversible mechanisms of action
[13]. Proteasome inhibitors can be of two types depending
upon the source of origin i.e. synthetic and natural. Borte-
zomib ( Valcade, PS-341), a dipeptide boronic acid, first of
its class of compounds, has been well studied for its prote-
asome inhibitory activity [14].Bortezomib was discovered
to be a synthetic proteasome inhibitor with reversible me-
chanism of action [15]. Long tested for its anti cancerTable 2 Table showing relationship between cell cycle arrests
different cancer types
Proteasome Inhibitor Cancer Type
Bortezomib Colorectal caner [8]
Malignant pleural mesothelioma (MPM), Breast canc
CML [42]
Glioblatoma multiforme (GBM) [28]
MG-132 Lung cancer (Calu 6) [46]
Cervical cancer [55]
Gastric cancer [47]
Sanggenon C Leukemia [13]
Isothiocyanates Multiple myeloma [12]
BSc2118 Multiple myeloma [11]
Celastrol Cervical cancer [62]properties in multiple myeloma, it was approved by FDA
for treatment of patients with multiple myeloma [16,17].
Bortezomib has also been shown to exert anti-cancer ac-
tivity against many cancer types [18,19]. More recently
compounds with irreversible mode of action are consid-
ered to be the second generation of proteasome inhibitors
and have shown promising results in clinical trials namely
Carfilzomib (PR-171), Salinosporamide A (NP-0052) and
MLN9708 [20,21]. Moreover many such compounds are
also being tested currently in pre-clinical studies on mul-
tiple cancer cell lines [9,22-26] (Table 1). Inhibition of pro-
teasomal activity targets the cancer cell in a multipronged
manner including, inhibition of proliferation and induc-
tion of cell cycle arrest, induction autophagy and apop-
tosis. As uncontrolled cell division is the root cause of any
cell acquiring malignancy, cell cycle and cell division are
popular targets for limiting cancer cell proliferation. Most
of the PIs studied till date arrest cancer cells in different
phases of cell cycle thereby deregulating cancer cell div-
ision (Table 2). Some cancer cells often develop resistance
to proteasome inhibition thereby limiting their use in can-
cer therapy. However the details of the related signaling
pathways and molecular mechanisms activated in res-
ponse to proteasome inhibition require detailed inves-
tigation. This review will briefly discuss some of these
signaling pathways / mechanisms regulated by PIs and
their possible role in influencing resistance to proteasome
inhibition therapy.
Proteasome inhibitors and cancer cell division
Proteasomes are critical for maintenance of cancer cell
division
Cell division in cells is the interplay of several cell cycle
regulatory proteins with restricted life span. Major pro-
teins related to cell cycle process are cyclins, cyclin
dependent kinases (CDKs), CDK inhibitors (CKIs) and




G2/M UBE2C, cyclin A and cyclin B1
er [51] G2/M p21
G2/M Rb, NF-ĸB
G2/M JNK, Cyclin B, p21, p27, CDK2, CDK4 and E2F4
S ROS generation and GSH depletion
G2/M ROS generation and GSH depletion
G2/M Macroautophagy
G0/G1 p27
G2/M p53, IĸB, ROS generation
G2/M p21, NF-ĸB
G2/M Autophagy and paraptosis
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rapid cell division by continuously reshuffling their core
partners for subsequent cell cycle phase transitions. Each
complex type is assigned a role in a particular cell cycle
phase and every time the replaced partner is degraded to
mark the onset of the next phase. Cyclin proteins are
found to be highly upregulated in cases of aberrant cell
division in cancer cells. Particularly cyclins D and E are
frequently upregulated in different cancer types [27,28].
This upregulation of cyclins is further supported by the
down regulation of another class of CDK regulatory pro-
teins, the CKIs, which bind, inactivate and degrade the
cyclin/CDK complex. Rapid proteasomal degradation of
CKIs in subsequent cell cycle phases contribute to the un-
controlled cell division in cancer cells. Recent studies have
established the involvement of ubiquitin proteasome path-
way (UPP) in degradation and recycling of the above
mentioned class of proteins, crucial for cancer onset and
progression [29]. The proteasomal degradation of proteins
is well complemented by the ubiquitin conjugating en-
zymes E1, E2 and E3 ligases, which add multiple ubiquitin
molecules to the proteasome substrate proteins. Mdm2,
Skp 1/Cul 1/F-box protein (SCF), Anaphase promot-
ing complex (APC), Ubiquitin-conjugating enzyme E2C
(UBE2C) are among the busiest ligases involved in cell
cycle regulation. Most of these enzymes target the prote-
olysis of tumor suppressor proteins like p53, p21 and p27.
The expression and activity of some of these enzymes has
also been reported to be altered by PIs in many cancer
cells [29]. Proteasomes are also involved in the regulation
of cell division in response to DNA damage response
(DDR) signals mediating F-box protein triggered degrad-
ation of cyclin D1 protein and G1 cell cycle arrest [30].
PIs disrupt cancer cell division
Proteasome inhibitors inhibit the activity of the pro-
teasome complex and in turn attenuate its protein deg-
radation activity. Therefore, PIs lead to the accumulation
of those proteins which are marked for ubiquitin-prote-
asome mediated degradation in cancer cells. These pro-
teins includes CKIs, various transcription factors, DNA
repair enzymes, kinases and cyclin dependent kinase
inhibitors (CKIs). Generally, the prime function of CKIs
lies in degrading cyclin/CDK complexes and disrupting
cell division. CKIs, p21 and p27 are known to be sup-
pressed in several cancer types and are attributed to can-
cer progression [31,32]. Bortezomib, along with other
PIs has been reported to significantly increase the expres-
sion of p21 and p27 proteins in many cancers thereby
causing cell cycle arrest [33-35]. On the other side prote-
asome inhibition also cause accumulation of the tumor
suppressor p53 which is a crucial component of cell cycle
regulation. PIs abrogate the degradation of p53 in cancer
cell reactivating its function in G1/S and G2/M arrest[29]. Another key component of PI mediated growth ar-
rest and apoptosis is inhibition of NFkB signaling and its
downstream target proteins mainly cyclin D, responsible
for G1/S transition and commitment to DNA synthesis
[36]. Accumulation of non degraded proteins increase
unfolded protein response (UPR) leading to induction of
endoplasmic reticulum stress which again causes cell cycle
arrest to release cells from this cellular stress. PIs induced
ROS generation in many cancers is responsible for DNA
damage mediated cell cycle arrest wherein cells rigorously
perform DNA repair mechanisms [36]. p53 along with
some other kinases either help in this process through
DNA repair enzymes or alternatively induce apoptosis in
case of serious genotoxic stress [37]. PIs have also been
reported to modulate the activity of MAPK pathways of
cell proliferation [36].Relationship between these signaling
pathways and proteasome inhibitors in cancer cells are
discussed in the subsequent portions of this review.
PI induced signaling pathways
NFkB signaling pathway: a favorite choice
NFkB is one of the major transcription factors critical
for inflammatory cytokine expression in many cancer
cells. NFkB signaling in cancer cells is controlled by the
ubiquitin proteasome pathway which directs the ubiqui-
tination and proteolysis of its inhibitory partner, IĸB.
Once freed from its inhibitor, NFkB gets localized in the
nucleus where it allows transcription of many genes
driving cancer cell proliferation [38]. NFkB pathway is
constitutively activated in cancers and play a crucial role
in conferring resistance to radiation and chemothera-
peutic agents in cancers [39,40].However, among many
proteins activated by NFkB, Cyclin D plays a crucial role
in carcinogenesis. Cyclin D binds to CDK 4/6 in the initial
phase of G1 to S phase transition where it performs two
major functions, hypophosphorylation of retinoblastoma
protein (Rb) [41] and protection of cyclin E/ CDK2 com-
plex from inhibitory effect of p21 and p27 [27] (Figure 1).
MAPK pathway: modulating cellular division
Mitogen activated protein kinases (MAPKs) family pro-
teins are involved in many processes of tumor develop-
ment and progression [39]. MAPK are associated with
cell survival and apoptosis in stressful cellular envi-
ronments [39]. Among the family members, ERK1/2
(p44/42) is associated with cell survival and tumor pro-
gression where as the other two members, p38 MAPK
and c-Jun N-Terminal kinases (JNK) are linked to either
cell survival or apoptosis [39]. Though not much has
been explored regarding how PIs modulate these path-
ways but there are evidences which clearly indicated
crosstalk between them [39]. According to a previous re-
port addition of PIs decreased the level of phosphoryla-
ted ERK1/2 in breast cancer cell lines through activation
Figure 2 MAPK pathways and Proteasome inhibitors: Proteasome
inhibitors modulate the members of MAPK pathway and control
cell cycle of cancer cells. PIs inhibit the activation of ERK 1/2 protein,
which is found to increase the expression of cyclin D1. PIs activate p38
MAPK which antagonizes the effect of ERK 1/2 and decrease cyclin D1.
PIs also activate JNK which is known to inhibit the E2F activity.
Figure 1 Regulation of NFkB, E2F/Rb and p53/p21 pathways of cell cycle arrest by PIs. Proteasome inhibitors block the degradation of IĸB,
an inhibitor of NFĸB via proteasome. This causes the accumulation of NF-ĸB in cytosol and represses its transcriptional activity which further
inhibits CyclinD1 expression. Decreased Cyclin D1 level terminates its binding to CDK4, which in turn fails to hypo-phosphorylate the Rb protein.
Once hypo-phosphorylation of Rb protein is ceased its hyper-phosphorylation by Cyclin E/ CDK2 complex is abrogated and its dissociation from
E2F and proteasomal degradation is also inhibited. Undissociated E2F fails to express CyclinA genes and genes involved in DNA synthesis and S
phase progression. On the other hand, proteasome inhibitors also inhibit mdm2 mediated degradation of p53 protein leading to the reactivation
of its transcriptional activity. p53 reactivation increases p21 expression, a CKI, which inhibit cyclin E/ CDK2 complex ceasing G1 phase progression.
However p21 also is known to inhibit cyclin B/ CDK1 complex causing G2/M arrest. Proteins like APC and cdc25 family members are also key
players in the sG2/M phase of cell cycle but their modulation by PIs still remains unclear.
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teasome pathway [39]. Ras / MEK/ERK pathway regula-
tes the expression of Cyclin D1 by modulating AP-1 and
ETS transcription factor, thereby playing a critical role in
G1 progression [42-44]. Bortezomib has also been docu-
mented to abrogate the activation of p44/42 (ERK1/2)
protein along with PI3K/Akt/mTOR and inhibition of
the nuclear export of HIF-1α, however its relation to cell
cycle arrest remains elusive [45]. Inactivation of ERK by
PIs may lead to cell cycle arrest in cancer cells. Secondly,
p38 MAP kinases signaling also modulate mammalian
cell cycle by antagonizing the effects of ERK mediated
Figure 3 Proteasome inhibitor induced ROS generation and cell
cycle arrest. Proteasome inhibitors increase the endogenous level of
reactive oxygen species which causes DNA damage by inducing
double strand breaks in intact DNA. PIs treatment leads to
accumulation of p53 which senses this DNA damage. p53 reactivation
upregulates p21 expression, a CDK inhibitor. p21 binds and inactivates
Cyclin B and CDK2 and causes G2/M cell cycle arrest in response to PIs.
Figure 4 Association of ER stress pathway and autophagy in
Proteasome inhibitor mediated cell cycle arrest. Proteasome
inhibitor treatment arrests the normal functioning of the
proteasome and increases the load of ubiquitinated and misfolded
proteins in cancer cells. This accumulation generates unfolded
protein response (UPR) and consequently ER stress. ER stress
generation enforces cells to be arrested in cell cycle phases and
induce autophagy in order to compensate and reduce the non-
functional protein load. At this stage autophagy can resolve the
normal cell state by digesting the non-functional proteins and
promote cancer cell survival or can trigger apoptosis leading to
cancer cell death. Autophagy inhibitors 3-MA and Bafilomycin A can
modulate the effect of autophagy induced cell cycle arrest or
apoptosis in association with PIs.
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cycle arrest. MG-132 treatment significantly increased
the phosphorylation of p38 MAPK in Calu-6 cells and
its inhibition partially inhibited MG-132 induced cell
death [46]. Lastly, c-Jun-N-terminal Kinase, the third
component of the MAPK pathway, has been reported to
be activated in MG-132 induced apoptosis [47]. Bortezo-
mib treatment activated JNK in glioblastma multiforme
(GBM) cells causing G2/M arrest with subsequent upre-
gulation of p21 and p27 proteins and simultaneous de-
crease in cyclin B, CDK2, CDK4 and E2F4 protein levels
[48]. More recently Bortezomib has also been reported
to activate JNK in head and neck cancer cells [49]. JNK1
binds and phosphorylates E2F and limit its ability to
bind to DNA, this may induce G1 arrest subsequent to
CDK mediated phosphorylation of pRb [50]. On the
other hand its activation leads to cell proliferation by
increasing the expression of cyclin D1 and repression of
p53 and p21 proteins [51,52]. However correlation of
JNK to the cell cycle arrest is still a matter of investiga-
tion. Involvement of MAPK pathways in cell cycle and
PI induced cell death pave the way for identification of
many of the novel targets which are supposed to provide a
mechanistic link between these two processes (Figure 2).
p53/21 pathway: blocking the doorstep of cell cycle entry
Transcription factor p53 lies in very close association
with both proteasome and cell cycle pathways [53]. Ithas been the most extensively studied protein of its class
in relation to PIs. In cancer cells, p53 protein is marked
for proteasomal degradation by mdm2 protein, a E3 type
of ubiquitin ligase [53-55]. Mdm2 ligase is found to be
highly expressed in cancers, though the underlying
mechanism is still unclear, possibly to keep p53 protein
away from tumor formation processes [56]. Proteasomal
inhibition allows accumulation of p53 and its nuclear ex-
port in cancer cells and thereby increase the expression
of its transcriptional target gene p21. p21, a potent CDK
inhibitor binds and inactivate cyclin E and the CDK2
complex. This complex is essential for late G1 phase of
cell cycle mediating entry in the S phase of cell cycle
(Figure 1). However activation of p53 and p21 proteins
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several other mediators of this pathway regulating PI in-
duced G0/G1 arrest.
Rb/E2F pathway: regulating DNA synthesis
Rapid proteasomal degradation of the retinoblastoma
protein is evident in several cancers. Many oncoproteins
are engaged in triggering ubiquitin proteasome degra-
dation of Rb including viral oncoprotein E7 of human
pappiloma virus type 16, Epstein-Barr virus nuclear anti-
gen 3C (EBNA3C) and gankyrin [57-62]. Rb act as a tu-
mor suppressor protein playing crucial role in cell cycle
regulation, DNA replication, DNA damage repair and
many other cellular processes. The preliminary role of
Rb in cell cycle regulation is binding and stabilization of
E2F family of proteins causing their transcriptional re-
pression. Transcriptionally repressed E2F becomes inef-
fective in activating genes required for DNA synthesis
and S phase progression [63]. Administration of PIs me-
diates Rb protein escape from proteasomal degradation.
Non-degraded Rb still remains bounded to E2F which
indirectly inhibits E2F mediated expression of S phase
progression genes thereby arresting cancer cells in G0/
G1 or S phase (Figure 1). According to a recent study ,
Bortezomib induced cell cycle arrest and apoptosis in
BCR/Abl expressing, imatinib resistant and sensitive CMLFigure 5 Refinement in PIs therapy via synergistic approaches. PIs can
effective targeting of PI resistant cancer cells and overcoming chemoresista
together cause cell cycle arrest via unfolded protein response and sometim
cycle arrest in combination with PIs thereby surpassing chemoresistance in
have also shown promising results in combination with PIs. This combinati
cell cycle arrest in cancer cells.cells. The molecular mechanism involved inhibition of
both NFĸB and phosphorylation of Rb eventually leading
to caspase dependent apoptosis [64]. However, more ela-
borate mechanism of cell cycle regulation by Rb/E2F path-
way is still not understood with respect to the proteasome
inhibitors.
DNA damage check point pathway: enforcing G2/M phase
arrest
Generally DNA damage checkpoint is imposed by for-
mation of double stranded breaks to the intact DNA by
any DNA damaging agent or generation of intracellular
ROS [65-68]. DNA damage and break in DNA replica-
tion process most often cause G2/M or S phase cell
cycle arrest [69-72]. Several reports have established that
PIs induced G2/M arrest in cancer cells by activation of
p53 and p21 proteins [73,74] (Figure 3). A recent study
has shown that PSI-341 treatment lead to p53 dependent
G2/M arrest upon co-treatment with DNA damaging
agent SN-38 [39]. PSI-341 also reduced the expression
of two p53 regulated proteins 14-3-3sigma and survivin
both of which regulate G2/M progression and apoptosis
[75]. p53 dependent G2/M arrest after generation of ROS
has also been reported in isothiocyanate treated multiple
myeloma cells [34]. MG-132 has been reported to cause
generation of ROS and depletion of the antioxidant GSHbe used in combination with different class of compounds for
nce. PIs can be combined with ER-stress modulators which can
es autophagy. Autophagy inhibitors have also shown to cause cell
duced by PIs in alone. One more class of compounds, HDAC inhibitors
on is reported to decrease NFkB activation and induces ROS leading to
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S and G2/M phase arrest respectively [46,76]. Other sig-
naling proteins viz, ATM, ATR, Chk1, Chk2 kinases and
cdc25 family of phosphatases also lie close to the pathway
DDR and promote cell cycle arrest both in p53 dependent
and independent manner. Recycling of these proteins is
performed by the UPP [77,78]. Though their role in PI
induced cell cycle arrest is a matter of further research.
Endoplasmic reticulum stress pathway inducing autophagy
mediating cell death
PIs increase the load of misfolded and ubiquitinated pro-
teins in cancer cells which elicit endoplasmic reticulum
stress. ER stress induced non-functional protein overload
leads to formation of autophagosome to digest these
intracellular proteins by a process known as macroauto-
phagy [49]. Macroautophgy induction is thought to over-
come the protein load and restore normal cell division
[79,80]. Autophagy is the process of degradation of in-
tracellular proteins next to ubiquitin proteasome path-
way and possess dual role in PI induced cancer cell death
or survival. A recent study demonstrated the involvement
of eIF2α-dependent pathway of autophagy induction in
prostate cancer cells upon PI treatment. This autophagy
induction induced a cytoprotective effect in prostate can-
cer cells which was alleviated when cells were co-treated
with autophagy inhibitors [81]. The exact mechanism of
autophagy induction followed by PI treatment still
remains obscure and needs detailed investigation. Borte-
zomib treatment induces autophagy in MCF-7 cells as a
compensatory mechanism to escape cell death which can
be restored upon co-treatment with 3-MA, an autophagy
inhibitor [82]. MG-132 induced G2/M arrest and apop-
tosis was also enhanced upon abolition of autophagy in
gastric cancer cells [83]. Similarly, celastrol, a natural PI,
resulted in the induction of autophagy and G2/M arrest in
HeLa cells. Interestingly it also caused paraptosis, forma-
tion of cytoplasmic vacuoles and apoptosis in multiple
cancer cell types [84]. On the contrary, MG-132 induced
cell death was partially attenuated on treatment with au-
tophagy inhibitor, 3-MA, which ensures the importance of
autophagy in PI, triggered cell death. However, induction
of autophagy is supposed to be primarily a defense mech-
anism to bypass the incidence of cell death after PI treat-
ment, still it remains to be a crucial event in PI induced
growth arrest of cancer cells (Figure 4). These studies
clearly indicate that the intricate mechanisms of associ-
ation of ER stress, autophagy and resistance to PI therapy
needs further investigation.
Conclusions and future perspectives
Development of chemoresistance against PIs and its in-
efficacy against many solid cancers necessitates a thorough
assessment of the treatment strategies involving PIs.Though not much has been explored in this context but
certain reports suggest that induction of autophagy post
PI treatment is a major cause of resistance to PI therapy
[85-87]. Therefore exploring synergistic drug combina-
tions with PIs for effectively combating chemoresistance
and limitations of targeted therapy could be a logical the-
rapeutic strategy. As discussed above proteasome inhibitor
induced cell cycle arrest is attributed to modulation of one
or more pathways. Therefore, the combination of PIs
along with the modulators of one of these signaling path-
ways, may possibly be explored for their therapeutic po-
tential in PI resistant cancer types. Already some reports
have indicated the potential of PIs in combination with
different class of compounds (Figure 5). Combination of
Bortezomib and autophagy inhibitor, Bafilomycin A1 in-
creases the cytotoxic effects against multiple myeloma
cells. Similarly, combination of PIs and ER stress inhibitor,
salubrinal potentiates toxicity in therapy resistant multiple
myeloma cells [88,89]. Recent studies also suggest the syn-
ergy between HDAC inhibitors (HDACi) and PIs against
multiple myeloma cell lines and have shown promising re-
sults in clinical trials [89]. PIs in combination with HDAC
inhibitors also induce cell cycle arrest via NFkB and ROS
pathways [90]. These findings provide new insights for
combination therapy of HDAC inhibitors and PIs [91,92].
Bortezomib has also been tested in combination with Nel-
finavir, an HIV protease inhibitor and the results have
indicated induction of ER stress, cell cycle arrest in cer-
vical cancer cells [93]. Several other combinations with
PIs worked out on different cancer cells given encouraging
results for combination therapy [94-100] is summarized in
Additional file 1: Table S1. However, there is an ever in-
creasing need for such synergistic combinations with
drugs from the synthetic and natural source for effectively
targeting cancer cells with PI resistance.
Additional file
Additional file 1: Table S1. List of combinations of PIs with different
class of compounds targeting cancer cell division.
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dependent kinase inhibitor; UPP: Ubiquitin proteasome pathway;
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3-MA: 3-Methyladenine; NF-ĸB: Nuclear factor kappa B; SCF: Skp 1/Cul 1/
F-box protein; APC: Anaphase promoting complex; UBE2C: Ubiquitin-
conjugating enzyme E2C; ROS: Reactive oxygen species.; JNK: c-jun-N-
terminal kinase; MAPK: Mitogen activated protein kinase; DDR: DNA damage
response; HDACi: Histone deacetylase inhibitors.
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